After pre-scheduled review of the safety and efficacy data of the first 40 patients, the Data Monitoring Committee has recommended to continue enrolment into the ADCAP trial.
After pre-scheduled review of the safety and efficacy data of the first 40 patients, the Data Monitoring Committee has recommended to continue enrolment into the ADCAP trial.